logo

For the Inventor, By the Inventor

Montreal, Canada

Joseph G Atkinson

This inventor holds 30 USPTO granted patents, primarily in Pharmaceutical Compounds. Top assignees: Merck + Co., Inc., Merck Frosst Canada, Inc., Merck Sharp + Dohme Corp.. Active years: 1976-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joseph G Atkinson. Retrieved from https://idiyas.com/inventor/joseph-g-atkinson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30

% Patents Active = 100.0

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 242(Granted Patents)


Location History:

  • Montreal, CA (1976 - 1993)
  • Kirkland, CA (1998)
  • Vancouver, CA (2001)

Company Filing History:

goldMedal17 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal9 out of 212 
 
Merck Frosst Canada, Inc.
 patents
bronzeMedal4 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
4. 1 out of 80 
 
Merck Frosst Canada & Co.
 patents
5. 1 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1976-2001

Loading Chart...
Areas of Expertise:
Prostaglandin Receptor Ligands
Cyclooxygenase-2 Inhibitors
Thrombolytic Therapy
Leukotriene Inhibitors
Heterocyclic Compounds
Antihypertensive Agents
Benzofuran Derivatives
Pyrrolo Compounds
Amino Acids
Deuteration
Functional Group Hydrocarbons
30 patents (USPTO):Explore Patents
1. 6277839 - Biphenylene lactams as prostaglandin receptor ligands (2001-08-21),
2. 5849943 - Stilbene derivatives useful as cyclooxygenase-2 inhibitors (1998-12-15),
3. 5221678 - (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the (1993-06-22),
4. 5188830 - Methods for thrombolytic therapy (1993-02-23),
5. 4962117 - Heterazole dialkanoic acids (1990-10-09),
6. 4933351 - Benzofuran 2-carbox amides useful as inhibitors of leukoriene (1990-06-12),
7. 4822803 - Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of (1989-04-18),
8. 4816457 - Aralkylaminoethanol heterocyclic compounds (1989-03-28),
9. 4749699 - 5-lipoxygenease inhibitors (1988-06-07),
10. 4745127 - Benzyl esters of benzofuran-2-carboxylic acids useful as inhibitors of (1988-05-17),
11. 4686222 - Aralkylaminoethanol heterocyclic compounds (1987-08-11),
12. 4663347 - Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene (1987-05-05),
13. 4656168 - (3-aralkylamino-2-or-propoxy)heterocyclic compounds in method of (1987-04-07),
14. 4634766 - 1,4-diaza-phenothiazines (1987-01-06),
15. 4568679 - Aralkylaminoethanol heterocyclic compounds (1986-02-04),

Title: Joseph G. Atkinson: A Pioneer in Pharmaceutical Innovations

Introduction

Joseph G. Atkinson is a prominent inventor based in Montreal, Canada, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 29 patents, Atkinson has played a vital role in advancing treatments for various medical conditions through innovative drug discovery.

Latest Patents

Among his latest patents, Atkinson developed biphenylene lactams as prostaglandin receptor ligands. This invention relates to biphenylene lactams of Formula II, which serve as ligands at the prostaglandin receptors. Furthermore, it includes a method for treating prostaglandin-mediated diseases by administering a non-toxic, therapeutically effective amount of the compound to patients in need of such treatment.

Another notable patent is for stilbene derivatives, which are useful as cyclooxygenase-2 inhibitors, further showcasing his dedication to addressing important health issues through innovative approaches.

Career Highlights

Joseph G. Atkinson has held positions at leading pharmaceutical companies, including Merck & Company, Inc. and Merck Frosst Canada, Inc. His work in these organizations has significantly influenced the development of effective therapeutic agents, contributing to the advancement of modern medicine.

Collaborations

Throughout his career, Atkinson has collaborated with esteemed colleagues, including Clarence S. Rooney and John J. Baldwin. These partnerships have fostered a collaborative environment that has further reinforced the importance of teamwork in scientific innovations and breakthroughs.

Conclusion

Joseph G. Atkinson's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents not only reflect his creativity and expertise but also serve as a testament to the impact that dedicated inventors can have on healthcare and patient treatment. Through ongoing research and collaboration, Atkinson continues to contribute to the ever-evolving landscape of pharmaceutical inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…